# Charles River Laboratories

Type: Company (CRL)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/charles-river-laboratories
Canonical HTML page: https://getbiobrief.com/entity/charles-river-laboratories

## Recent coverage (1 stories)

### 40%+ revenue from small biotech gives Charles River an edge in funding rebound
2026-06-19 02:33:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Morgan Stanley’s divergent ratings on Charles River and IQVIA reflect how biotech funding cycles drive CRO demand. For biotech and pharma executives, the CRL upgrade signals that contract research capacity for preclinical and lab testing may tighten as capital flows back into early-stage drugmakers.
Full story: https://getbiobrief.com/story/crol-biotech-funding-recovery-impact

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.